Zobrazeno 1 - 10
of 19
pro vyhledávání: '"carboxyamidotriazole-orotate"'
Publikováno v:
Jichu yixue yu linchuang, Vol 44, Iss 4, Pp 440-446 (2024)
Objective To study the effect of carboxyamidotriazole-orotate(CTO) on the proliferation and fatty acid anabolism regulation of human pancreatic cancer cells. Methods Human pancreatic cancer cell lines AsPC-1, AsPC-1/GEM(AR), PANC-1 and MiaPaCa-2 were
Externí odkaz:
https://doaj.org/article/1396c3c1c3274e42bf5469d441e53374
Publikováno v:
Jichu yixue yu linchuang, Vol 42, Iss 5, Pp 701-707 (2022)
Objective To explore regulation mechanism of carboxyamidotriazole-orotate (CTO) on oncogenic phenotype of mouse glioma-associated macrophages. Methods Bone marrow-derived macrophages(BMDMs) or RAW264.7 macrophages (tumor associated macrophages,TAMs)
Externí odkaz:
https://doaj.org/article/e4c555910d4f4b6a8d2545ef4fa0b019
Publikováno v:
Jichu yixue yu linchuang, Vol 41, Iss 7, Pp 957-962 (2021)
Objective To investigate the effects of carboxyamidotriazole-orotate (CTO) on the proliferation and apoptosis of mouse glioma cell line GL261. Methods The proliferation of GL261 cells was detected by live cell counting. Cell cycle of GL261 cells was
Externí odkaz:
https://doaj.org/article/574ad4d1ab794f1898521c165e9ec4e9
Autor:
Manjulika Das
Publikováno v:
The Lancet. Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d77adb4e9e84602ae1d1cc2532d121
https://pubmed.ncbi.nlm.nih.gov/29731337
https://pubmed.ncbi.nlm.nih.gov/29731337
Autor:
Elizabeth Garrett-Mayer, Ingo K. Mellinghoff, Lisa M. DeAngelis, Katharine McNeill, Thomas Kaley, Timothy A. Chan, Robert Terziev, Cameron Brennan, Malbora Manne, Andrew Caterfino, Eli L. Diamond, Debyani Chakravarty, Robert J. Young, Rashida A. Karmali, Michael Lamson, Kathryn Beal, Greg Gorman, Philip H. Gutin, Viviane Tabar, Alissa A. Thomas, Mariza Daras, Elena Pentsova, Linda M Bavisotto, Antonio Omuro, Krishna Patel, Andrew T. McKeown, Xuling Lin, I. T. Gavrilovic
Purpose Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non–voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and synergistic effects with temozolomide (TMZ) in glioblastoma (GBM) models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cfbf598d8c80172c56f3a3f7431108d
https://europepmc.org/articles/PMC5993168/
https://europepmc.org/articles/PMC5993168/
Autor:
Alan Sandler, Antonio Omuro, Greg Gorman, Walter J. Urba, Matthew H. Taylor, Rashida A. Karmali
Publikováno v:
Journal of Cancer Therapy. :322-333
Pre-clinical studies suggest carboxyamidotriazole orotate (CTO) demonstrates anti-tumor activity through modulation of multiple tyrosine kinase signaling pathways and interactions with the tumor microenvironment. We determined the safety and tolerabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06f691739381c3a4ca737f78a70e8cd0
https://doi.org/10.4236/jct.2015.64035
https://doi.org/10.4236/jct.2015.64035
Publikováno v:
Journal of Cancer Therapy. :857-871
Background: Paclitaxel (PTX) is approved for the treatment of refractory ovarian cancer and breast cancer, but is problematic due to severe, dose-dependent, potentially irreversible neurotoxicity. Alternative formulations using nanoparticles and lipo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::877ae2268150f680ecf4627f3e6eee9b
https://doi.org/10.4236/jct.2013.44098
https://doi.org/10.4236/jct.2013.44098
Autor:
Elena Pentsova, Linda M Bavisotto, Malbora Manne, Xuling Lin, Mariza Daras, Igor T. Gavrilovic, Antonio Omuro, Lisa M. DeAngelis, Jessica Hansen, Thomas Kaley, Ingo K. Mellinghoff, Andrew T. McKeown, Greg Gorman, Michael Lamson, Rashida A. Karmali
Publikováno v:
Journal of Clinical Oncology. 34:2064-2064
2064Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling that results in simultaneous modulation of several receptor-mediated calcium-dependent signaling pathways. This s...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba16e2223ae05a853f76a279e4307e3c
https://doi.org/10.1200/jco.2016.34.15_suppl.2064
https://doi.org/10.1200/jco.2016.34.15_suppl.2064
Autor:
Katharine McNeill, Lisa M. DeAngelis, Antonio Omuro, Robert J. Young, Thomas Kaley, Michael Lamson, Kathryn Beal, Barry Douglas Anderson, Alissa A. Thomas, Ingo K. Mellinghoff, Brandon Burch, Timothy A. Chan, Eli L. Diamond, Julio Arevalo Perez, Rashida A. Karmali, Yoshiya Yamada
Publikováno v:
Journal of Clinical Oncology. 34:2060-2060
2060Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling achieving simultaneous modulation of several receptor-mediated signaling pathways. A single-agent phase I trial d...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9e2d678715be6aaca9fcc561627b184
https://doi.org/10.1200/jco.2016.34.15_suppl.2060
https://doi.org/10.1200/jco.2016.34.15_suppl.2060
Publikováno v:
Journal of Solid Tumors. 2
Background: Carboxyamidotriazole orotate (CTO) is the orotic acid salt of 5-amino-1(4-(4-chlorobenzoyl)-3, 5-dichlorobenzyl)-1, 2, 3-triazole-4-carboxamide (CAI). CTO possesses increased solubility as compared to CAI as the free base. The antiprolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8eee7b5d1bdd34a63a29154ee923c5b
https://doi.org/10.5430/jst.v2n5p13
https://doi.org/10.5430/jst.v2n5p13